Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.”

A startup developing a one-time treatment that is intended to rewind the clock on dying cells announced a major influx of funding. Life Biosciences, a

Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.

A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B

The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.